Godavari Biorefineries Ltd

Godavari Biorefineries Limited informed the National Stock Exchange of India Limited and BSE Limited that MUFG Intime India Private Limited, the company's Registrar and Share Transfer Agent, has issued a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026, confirming the acceptance and rejection of securities received for dematerialisation and subsequent listing on stock exchanges.

Godavari Biorefineries Limited announced that its shareholders approved the re-appointment of Dr. Raman Ramchandran and Mr. Suhas Godage as directors liable to retire by rotation at the company's 71st Annual General Meeting held on September 28, 2026. The company also approved the re-appointment and remuneration of Mr. Samir S. Somaiya as Managing Director, and Mr. Suhas Godage as Executive Director (Works -Sakarwadi), both effective April 1, 2027. Additionally, the shareholders approved the appointment of Mr. Dinesh Sharma as a director and his remuneration as a whole-time director designated as Executive Director (Works -Sameerwadi) for a period of three years, also effective September 28, 2026.

Somaiya Chemicals Limited informed the National Stock Exchange of India Limited and BSE Limited that the trading window for dealing in the company's securities will be closed for directors, key managerial persons, designated persons, and their immediate relatives from October 1, 2026, until 48 hours after the declaration of the unaudited financial results for the quarter and half year ended September 30, 2026.

Godavari Biorefineries Ltd., a producer of ethanol and bio-based specialty chemicals, announced its financial results for the quarter ended June 30, 2026, reporting total income of Rs 559.9 crore, compared to Rs 534.0 crore in the year-ago quarter, while its earnings before interest, taxes, depreciation and amortization were Rs 2.6 crore, down from Rs 6.5 crore in Q1 FY26. The company commissioned a 200 KLPD grain-based distillery at Sameerwadi, increasing its total ethanol capacity to 800 KLPD, and secured an Indian patent for a cost-effective process to manufacture branched alcohols.

Godavari Biorefineries will hold a meeting of the Board of Directors of the Company on 5 August 2026.

The company currently operates a 600 KLPD distillery based on sugarcane juice and syrup. The newly commissioned capacity of 200 KLPD has been set up at an estimated cost of Rs 130 crore, financed through internal accruals and debt. According to the company, the addition of the grain-based distillery provides dual-feedstock capability, enabling more resilient ethanol production by reducing dependence on sugarcane and ensuring operational continuity during climate-related disruptions. Godavari Biorefineries is a leading integrated biorefinery focused on the production of bio-based chemicals, ethanol, sugar, and power. The company is among the larger ethanol producers in India and is a pioneer in manufacturing ethanol-based chemicals. It operates advanced manufacturing facilities at Sakarwadi in Maharashtra and Sameerwadi in Karnataka, along with three research and development centres located in Mumbai and its plant locations. On the financial front, the company reported a 26.48% decline in consolidated net profit to Rs 52.88 crore for the quarter ended March 2026, compared with Rs 71.93 crore in the corresponding quarter of the previous year. Consolidated sales declined 2.66% to Rs 564.10 crore during the quarter from Rs 579.50 crore recorded in the same period last year.Powered by Capital Market - Live

Godavari Biorefineries announced that the Japanese Patent Office has granted its patent, 5-HYDROXY 1,4-NAPHTHALENEDIONE FOR USE IN THE TREATMENT OF CANCER,. This patent covers a novel class of compounds that exhibit strong inhibitory effects on cancer and cancer stem cells, demonstrating significant efficacy against multiple types, including breast and prostate cancer.

According to the company, the patent covers a novel class of compounds that have demonstrated strong inhibitory effects on cancer cells and cancer stem cells. The compounds have shown significant efficacy against multiple cancer types, including breast and prostate cancer, highlighting their potential therapeutic applications. Godavari Biorefineries is a leading integrated biorefinery focused on the production of bio-based chemicals, ethanol, sugar, and power. The company is among the larger ethanol producers in India and is a pioneer in manufacturing ethanol-based chemicals. It operates advanced manufacturing facilities at Sakarwadi in Maharashtra and Sameerwadi in Karnataka, along with three research and development centres located in Mumbai and its plant locations. On the financial front, the company reported a 26.48% decline in consolidated net profit to Rs 52.88 crore for the quarter ended March 2026, compared with Rs 71.93 crore in the corresponding quarter of the previous year. Consolidated sales declined 2.66% to Rs 564.10 crore during the quarter from Rs 579.50 crore recorded in the same period last year. Powered by Capital Market - Live

Net profit of Godavari Biorefineries declined 26.48% to Rs 52.88 crore in the quarter ended March 2026 as against Rs 71.93 crore during the previous quarter ended March 2025. Sales declined 2.66% to Rs 564.10 crore in the quarter ended March 2026 as against Rs 579.50 crore during the previous quarter ended March 2025. For the full year,net profit reported to Rs 3.53 crore in the year ended March 2026 as against net loss of Rs 23.41 crore during the previous year ended March 2025. Sales rose 6.29% to Rs 1987.94 crore in the year ended March 2026 as against Rs 1870.25 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales564.10579.50 -3 1987.941870.25 6 OPM %15.2819.40 -6.395.54 - PBDT80.81108.58 -26 90.2048.52 86 PBT66.8995.74 -30 35.71-1.54 LP NP52.8871.93 -26 3.53-23.41 LP Powered by Capital Market - Live

Godavari Biorefineries will hold a meeting of the Board of Directors of the Company on 22 May 2026.